Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics
Vertex Pharmaceuticals Incorporated (VRTX)
Today's Latest Price: $211.58 USD
Updated Oct 23 4:00pm
Add VRTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
VRTX Stock Summary
- VRTX has a market capitalization of $55,057,585,061 -- more than approximately 96.38% of US stocks.
- Over the past twelve months, VRTX has reported earnings growth of 158.49%, putting it ahead of 92% of US stocks in our set.
- The volatility of Vertex Pharmaceuticals Inc's share price is greater than that of only 6.98% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Vertex Pharmaceuticals Inc are MU, AMAT, LRCX, EA, and XLNX.
- VRTX's SEC filings can be seen here. And to visit Vertex Pharmaceuticals Inc's official web site, go to www.vrtx.com.
VRTX Stock Price Chart Interactive Chart >
VRTX Price/Volume Stats
| Current price | $211.58 | 52-week high | $306.08 |
| Prev. close | $210.08 | 52-week low | $189.35 |
| Day low | $209.07 | Volume | 1,715,700 |
| Day high | $213.51 | Avg. volume | 1,822,409 |
| 50-day MA | $261.03 | Dividend yield | N/A |
| 200-day MA | $259.02 | Market Cap | 55.11B |
Vertex Pharmaceuticals Incorporated (VRTX) Company Bio
Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.
VRTX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $211.58 | $43507.12 | 20482% |
Below please find a table outlining a discounted cash flow forecast for VRTX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Vertex Pharmaceuticals Inc ranked in the 98th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 20583.33% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. The most interesting components of our discounted cash flow analysis for Vertex Pharmaceuticals Inc ended up being:
- The compound growth rate in the free cash flow of Vertex Pharmaceuticals Inc over the past 3.75 years is 2.59%; that's better than 93.01% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet reveals debt to be 1% of the company's capital (with equity being the remaining amount). Approximately merely 5.06% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- VRTX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 55.95% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 20079% |
| 1% | 20281% |
| 2% | 20482% |
| 3% | 20684% |
| 4% | 20886% |
| 5% | 21088% |
KMDA, ASNB, GEN, AMEH, and AMRX can be thought of as valuation peers to VRTX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...